Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, for Recurrent SCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Tarlatamab, a first-in-class DLL3-targeted bispecific T cell engager, in recurrent small-cell lung cancer: an open-label, phase 1 study
J. Clin. Oncol 2023 Jan 23;[EPub Ahead of Print], L Paz-Ares, S Champiat, WV Lai, H Izumi, R Govindan, M Boyer, HD Hummel, H Borghaei, ML Johnson, N Steeghs, F Blackhall, A Dowlati, N Reguart, T Yoshida, K He, SM Gadgeel, E Felip, Y Zhang, A Pati, M Minocha, S Mukherjee, A Goldrick, D Nagorsen, NH Sadraei, TK OwonikokoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.